NEW YORK, NY / ACCESSWIRE / March 17, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Opera Limited (NASDAQ:OPRA)
Investors Affected: (a) Opera American depositary shares pursuant and/or traceable to the Company's initial public offering commenced on or about July 27, 2018 and/or (b) Opera securities between July 27, 2018 and January 15, 2020,
A class action has commenced on behalf of certain shareholders in Opera Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Opera's sustainable growth and market opportunity for its browser applications was significantly overstated; (ii) Defendants' funded, owned, or otherwise controlled loan services applications and/or businesses relied on predatory lending practices; (iii) all the foregoing, once revealed, were reasonably likely to have a material negative impact on Opera's financial prospects, especially with respect to its lending applications' continued availability on the Google Play Store; and (iv) as a result, the Offering Documents and Defendants' statements were materially false and/or misleading and failed to state information required to be stated therein.
Shareholders may find more information at https://securitiesclasslaw.com/securities/opera-limited-loss-submission-form/?id=5719&from=1
Geron Corporation (NASDAQ:GERN)
Investors Affected: March 19, 2018 - September 26, 2018
A class action has commenced on behalf of certain shareholders in Geron Corporation. The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/geron-corporation-et-al-loss-submission-form/?id=5719&from=1
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Investors Affected: February 14, 2020 - March 9, 2020
A class action has commenced on behalf of certain shareholders in Inovio Pharmaceuticals, Inc. According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.
Shareholders may find more information at https://securitiesclasslaw.com/securities/inovio-pharmaceuticals-inc-loss-submission-form/?id=5719&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com:
https://www.accesswire.com/581279/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-OPRA-GERN-and-INO
